 Gritstone bio Inc NASDAQ: GRTS has announced updated results from the Phase 12 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors. The immunotherapy is a heterologous prime-boost in combination with Bristol-Myers Squibb Cos NYSE: BMY Opdivo nivolumab, and Yervoy ipilimumab. 